Certara, Inc. (CERT)
After hours:
| Previous Close | 22.52 |
| Open | 22.63 |
| Bid | 8.60 x 1000 |
| Ask | 21.49 x 3200 |
| Day's Range | 21.15 - 22.81 |
| 52 Week Range | 16.17 - 45.48 |
| Volume | |
| Avg. Volume | 536,246 |
| Market Cap | 3.429B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.09 |
| Earnings Date | Aug 03, 2022 - Aug 08, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 25.00 |
- GlobeNewswire
Certara Introduces New Simcyp™ Discovery Simulator for Early-Stage and Translational Drug Development
Advances lead optimization, first-in-human dose prediction and formulation developmentPRINCETON, N.J., June 28, 2022 (GLOBE NEWSWIRE) -- Certara (Nasdaq: CERT), a global leader in biosimulation, today announced the release of Simcyp Discovery Simulator, a new software designed for scientists working in small molecule drug discovery and translational research. Derived from the industry-leading Simcyp Simulator, Simcyp Discovery increases confidence in early-stage development decisions using physi
- GlobeNewswire
Certara Announces New Versions of Biosimulation Software for Development of Novel Biologics
New capabilities enhance clinical predictability for different compounds across more therapeutic areasPRINCETON, N.J., June 21, 2022 (GLOBE NEWSWIRE) -- Certara, a global leader in biosimulation, today announced the release of new versions of its Immunogenicity (IG), Immuno-oncology (IO) and Vaccine Simulators to help predict how drugs work and address key questions in the development of novel biologic therapies. “The latest versions of our simulators help tackle some of the toughest challenges
- Motley Fool
Certara, Inc. (CERT) Q1 2022 Earnings Call Transcript
On the call from Certara, we have William Feehery, chief executive officer; and Andrew Schemick, chief financial officer. Earlier today, Certara released financial results for the quarter ended March 31st, 2022.
